Ocular Therapeutix Appoints David W. Robinson as Global Chief Commercial Officer

Accomplished global commercial leader with deep expertise in retina drug launches

Primary architect for the industry-defining launch of EYLEA while at Regeneron

Most recently served as Chief Marketing Officer, Global Ophthalmology at Merck

BEDFORD, Mass., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that David W. Robinson has agreed to join the Company as Global Chief Commercial Officer. The appointment of Mr. Robinson, a proven commercial leader with a history of launching category-defining therapies, strategically positions Ocular for success in its global launch of AXPAXLI (also known as OTX-TKI), in development for wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR), if approved.

“We are delighted to welcome David to Ocular Therapeutix. He is an exceptional leader who will play an invaluable role in guiding the global launch and commercialization of AXPAXLI, if approved, as we continue to accelerate our NDA timeline and advance launch preparedness. Few executives in retina have David’s track record. When you think of successful drug launches, EYLEA rises to the top, and it is a privilege to have a key architect of that launch place his trust in the future of Ocular,” said Pravin U. Dugel, MD, Executive Chairman, President and Chief Executive Officer of Ocular Therapeutix. “In addition to playing a pivotal role in the launch of EYLEA at Regeneron, David most recently was at Merck, where he led global ophthalmology marketing efforts, including for the recently acquired EyeBio assets. We view AXPAXLI as having truly global potential, and David’s U.S. and international experience will uniquely position Ocular to execute at scale in wet AMD and diabetic retinal disease.”

Mr. Robinson will have primary responsibility for Ocular’s global commercial franchise, serve as a member of Ocular’s Executive Leadership Team, and report directly to Pravin U. Dugel, MD. Steve Meyers will continue in his role as Chief Commercial Officer and work closely with Mr. Robinson to develop the AXPAXLI launch readiness plan, while continuing to lead the DEXTENZA marketing efforts.

“I am thrilled to join Ocular Therapeutix at such a pivotal moment in the Company’s life cycle,” commented David Robinson, Global Chief Commercial Officer of Ocular Therapeutix. “My experience leading the launch of EYLEA showed me firsthand how meaningful innovation, coupled with disciplined execution, can reshape treatment paradigms and create entirely new standards of care. I see similar potential with AXPAXLI, a product candidate with global potential and expansive opportunities, beginning with wet AMD and diabetic retinal disease – where registrational programs are well underway – and ultimately extending to other retinal vascular diseases. AXPAXLI represents one of the rare product profiles that has the capability to deliver value across the retina ecosystem: improving patient outcomes, simplifying practice logistics for providers, and offering a more efficient and predictable profile for payors. Upon approval, I look forward to bringing this important therapy to patients around the world.”